Yahoo
NasdaqGM - Nasdaq Real Time Price USD

BioHarvest Sciences Inc. Common Stock (BHST)

1.5700 -0.0800 (-4.85%)
At close: November 2 at 4:00:00 PM EST
Chart Range Bar
Loading chart for BHST
  • Previous Close 1.6500
  • Open 1.6300
  • Bid 2.1400 x 100
  • Ask 2.2800 x 100
  • Day's Range 1.5600 - 1.6500
  • 52 Week Range 1.3710 - 9.2500
  • Volume 20,812
  • Avg. Volume 37,978
  • Market Cap (intraday) 35.589M
  • Beta (5Y Monthly) 1.29
  • PE Ratio (TTM) --
  • EPS (TTM) -0.5100
  • Earnings Date Nov 12, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 10.50
  • Zacks Rating Neutral

BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science-based health and wellness nutraceutical solutions that are manufactured and sold as dietary supplements and functional food and beverages, as well as the manufacturing, marketing, and sale of science-based health, pharmaceutical, and cosmeceutical solutions. The company also provides contract development and manufacturing operation services. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red wine. The company has a strategic collaboration with Tate & Lyle plc for the development of plant-based sweetener molecules. The company is based in Vancouver, Canada.

www.bioharvest.com

89

Full Time Employees

December 31

Fiscal Year Ends

Packaged Foods

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BHST
69.75%
S&P 500 (^GSPC)
10.17%

1-Year Return

BHST
82.46%
S&P 500 (^GSPC)
10.25%

3-Year Return

BHST
63.82%
S&P 500 (^GSPC)
74.66%

5-Year Return

BHST
85.71%
S&P 500 (^GSPC)
62.86%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 8.84M
Earnings -3.71M
Profit Margin -42.04%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
5M
-40.0%
-35.0%
-30.0%
-25.0%

Analyst Insights

View More

Analyst Price Targets

5.00
10.50 Average
1.5700 Current
15.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/12/2026
Analyst Maxim Group
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 12 -> 5

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -31.21%

  • Return on Assets (ttm)

    -11.02%

  • Return on Equity (ttm)

    -142.50%

  • Revenue (ttm)

    35.48M

  • Net Income Avi to Common (ttm)

    -11.07M

  • Diluted EPS (ttm)

    -0.5100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    16.22M

  • Total Debt/Equity (mrq)

    79.41%

  • Levered Free Cash Flow (ttm)

    -11.85M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: